Intralytix announced today that it has received the highly coveted Safe Quality Food (SQF) certification for food manufacturing

Columbia, Maryland, USA – January 18, 2024. Intralytix, Inc. announced today that its food safety product, EcoShield™, has been granted a supplement to its GRAS (Generally Recognized As Safe) GRN 000834 status from the Food and Drug Administration (FDA)

Columbia, Maryland, USA – January 18, 2024. Intralytix, Inc. announced today that its food safety product, SalmoFresh™, has been granted a supplement to its GRAS (Generally Recognized As Safe) GRN 000435 status from the Food and Drug Administration (FDA)

Columbia, Maryland, USA. – October 9, 2023 – Intralytix, Inc. announced today that it has been issued a patent by the European Patent Office covering its Shigella bacteriophages and their various applications. The patent broadly relates to several bacteriophages with strong lytic potency against Shigella spp., and their various formulations.

Columbia, Maryland - September 12, 2023 - Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of its phage therapy product VRELysin™ in significantly reducing or eliminating vancomycin-resistant enterococci (VRE) levels in the human gastrointestinal tract.

Intralytix, Inc. announced today that the clinical trial “A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of EcoActive on Intestinal Adherent Invasive Escherichia coli (AIEC) in patients with inactive Crohn’s disease (CD),” will begin enrolling at the Johns Hopkins University (JHU) at various locations throughout the Baltimore metro area in Maryland (USA).

Intralytix, Inc. today announced successful, full enrollment of its Phase 1 clinical trial at the University of Maryland’s School of Medicine (UMSOM) in Baltimore under the direction of Dr. Wilbur Chen, Professor of Medicine and Chief of Adult Clinical Studies at UMSOM’s Center for Vaccine Development and Global Health (CVD).

Intralytix, Inc., announced today that it has received a SBIR Phase III grant (Award No. 2023-70439-39191) from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA)'s Meat and Poultry Processing Research and Innovation Program, to optimize SalmoFresh™ application at small and medium poultry and meat producers.

Intralytix, Inc. today announced the launch of a Phase 1/2a clinical trial to assess the safety and efficacy of Intralytix phage therapy product ShigActive™ to prevent or reduce the severity of Shigella infections.

Intralytix, Inc. announced today that it has received a Phase II contract in the amount of $1,498,045. This contract is made through the Small Business Innovation Research (SBIR) program from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This project is the continuation of a successfully completed NIAID-funded Phase I contract.

Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product VRELysin™, a bacteriophage preparation to manage colonization of vancomycin resistant Enterococcus (VRE) in the human gut.

Both companies believe there is potential to use the abundant probiotic microorganisms to intensify natural processes, thereby tackling bacteria and boosting gut health without the need for broad spectrum antibiotic medication.

Intralytix, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product ShigActive™, a bacteriophage preparation to manage Shigella infections in humans.

Intralytix, Inc. announced today that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966.

By harnessing the natural power of these bacteriophages, Intralytix offers robust food safety products designed to target some of the deadliest foodborne bacterial pathogens, including L. monocytogenes and E. coli.

Intralytix, Inc. announced today that it has received a Phase I award in the amount of $299,672 with an option for a Phase II award in the amount of $1,498,045. This award is made through the Small Business Innovation Research (SBIR) program under a Fast-Track Phase I / Phase II program providing for up to $1.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

Intralytix, Inc. announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Food and Agriculture (NIFA), an agency of the U.S. Department of Agriculture (USDA), for the development of a phage biocontrol solution for Vibrio parahaemolyticus in various food products, including seafood.

Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications.

Intralytix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.

Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella.

Intralytix, Inc. announced today that its food safety product, SalmoFresh™, has been granted a supplement to its GRAS (Generally Recognized As Safe) recognized status from the Food and Drug Administration (FDA), which expands the use of SalmoFresh™ to ready-to-eat and raw red meat carcasses, subprimals and trimmings.

Intralytix, Inc. announced today that its broader acting and expanded use food safety product, EcoShield PX™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA) for elimination of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli (STEC) in many foods, including ground beef.

Intralytix announces joint collaboration agreement to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health.

Intralytix, Inc. announced today that it has closed on the acquisition of a 33,000 sq. ft. building in Columbia, Maryland. The facility, located in the Columbia Gateway Community, will serve as the Company's new headquarters.

Intralytix, Inc. announced today that it received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical trials at Mount Sinai hospital in New York, NY.

Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize phage-based products.

Intralytix, Inc. announced today that its latest food safety product, ShigaShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.

Intralytix, Inc., announced today that the company has received a SBIR Phase II grant from the U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA).

Intralytix, Inc., announced today that it has entered into a collaboration agreement with Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group headquartered in St. Prex, Switzerland.

Intralytix, Inc. announced today that its food safety product, ListShield™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Intralytix, Inc. announced today that the company has received a SBIR Phase I grant from the U.S. Department of Agriculture (U.S.D.A.) to develop a bacteriophage (or phage) cocktail effective against the shellfish pathogen Vibrio tubiashii.

Intralytix, Inc. announced today that its latest food safety product, SalmoFresh™, has received GRAS (Generally Recognized As Safe) recognition from the Food and Drug Administration (FDA).

Intralytix, Inc. announced today that it has entered into a Multiple Project Collaboration Agreement ("MPCA") with The Procter & Gamble Company (NYSE:PG).

Intralytix, Inc. announced today that it has been awarded a grant under a National Institute of Food And Agriculture (NIFA) / United States Department of Agriculture (USDA) Small Business Innovative Research (SBIR) Grants Program.

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for EcoShield™.

Intralytix, Inc. announced today that it has received a U.S. Army Phase II STTR contract supporting the further development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Food Safety News March 22, 2011 Company Develops Natural Way to Fight E. coli

Intralytix, Inc. announced today that its Chief Scientific Officer, Dr. Alexander Sulakvelidze, has been appointed Editor-In-Chief of a new scientific journal called "Bacteriophage."

Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield™ food safety product, effective against E. coli O157:H7.

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a phage-based product.

Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product.

Intralytix, Inc. announced today that it has been awarded a contract from the U.S. Army to develop a bacteriophage-based food safety product for reducing or eliminating contamination from pathogenic

Intralytix, Inc., announced today that it has been issued a patent by the U.S. Patent & Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection including MRSA.

Intralytix, Inc., announced today that it has been named a recipient of a 2009 Army Commercialization Pilot Program (CPP) grant to support a phage-based technology development

National Public Radio - April 4, 2008 Using 'Phage' Viruses to Help Fight Infection NPR Talk of the Nation:  Science Friday with Intralytix Vice President, Alexander Sulakvelidze

Intralytix, Inc., announced today that it has won the Popular Science "Best of What's New" award for its food safety product ListShield™.

Intralytix, Inc. announced today that the Food and Drug Administration has approved LMP 102 for use on ready-to-eat food.

CRC Press - December 28, 2004 Bacteriophages: Biology and Applications 528 page book provides a comprehensive overview of phage history, biology, techniques, and applications

Phage biocontrol - an emerging modern technology now going mainstream for improving food safety.

Intralytix once again selected as 2024 “Top Food Safety Solutions Provider” by the Food and Beverage Technology Review magazine.

On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting.

Bacteriophages could be crucial weapons in the fight against antibiotic-resistant bacteria.

Bacteria-killing viruses, called bacteriophages, are increasingly being used to destroy harmful microbes during food processing, to stop food rotting and to treat plant and animal diseases on farms.

Every year, one in seven people in America comes down with a foodborne illness, typically caused by a bacterial pathogen, including E.Coli, listeria, salmonella, or campylobacter

An interview with Alexander "Sandro" Sulakvelidze, President and CEO of Intralytix, Inc.

Maryland is a hotspot for research and production of superbug-killing bacteriophages.

If you thought food poisoning was just a matter of the occasional stomach upset from a dodgy shrimp or two, the CDC has some unsettling numbers for you.

Intralytix, the largest food safety phage company in the world, sits on the precipice of substantial growth and success. 23 years of building unrivaled bacteriophage expertise, developing and securing 15 issued patents, and being one of two phage companies in the world with sales revenue have put this Columbia, Maryland-based company in a position to harness several positive macro-market forces to fuel its expansion.

Intralytix, Inc.'s EcoActive™ bacteriophage therapy targeting adhesive invasive E. coli (AIEC) in Crohn's disease patients has entered a Phase 1/2a clinical trial.

Intralytix is holding a contest for the creation of cartoon characters depicting bacteriophages.

Intralytix, Inc. receives a U.S. Army award in support of studies on elucidating the interaction of bacteriophages with bacteria in various food matrixes and selected food safety interventions on the food microbiome.

Intralytix, Inc. announced that it has entered into a collaboration agreement for developing bacteriophage preparations against selected bacterial pathogens.

Bacteriophages: Nature's Answer to Killing Pathogens in Fresh Pet Food.

In the most recent report, Lux rated Intralytix as superior in 8 out of 10 categories used to rank the competitive companies.

Intralytix Inc's product targeting Shigella has received GRAS (Generally Recognized As Safe) recognition from the US Food and Drug Administration (FDA).

FDA on a Witch Hunt Against Commercial Pet Food? A Little Spritz of This Makes Pet Food Far Safer.

Intralytix wins grant from the U.S. Department of Agriculture to develop a phage cocktail that will be effective against the pathogens that kill larval shellfish.

Intralytix is exhibited at the World Congress on Beneficial Microbes in Valencia, Spain

Seafood Expo North America/Seafood Processing North America (SENA) March 15-17, 2015 Intralytix at the SENA, Boston Convention & Exhibition Center, Boston, MA, USA

Intralytix Receives Additional Regulatory Clearance for SalmoFresh™ - Phage-Based Food Safety Product Effective Against Salmonella.

Health Canada December 12, 2014 Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry, smoked salmon, fresh-cut apples, and long leaf lettuce

Health Canada October 31, 2014 Health Canada approved the use of ListShield™ as a processing aid for ready-to-eat meat and poultry

Health Canada October 16, 2014 Health Canada approved the use of EcoShield™ as a processing aid for red meat

Health Canada August 26, 2014 Health Canada approved the use of SalmoFresh™ as a processing aid for various foods in Canada, in all jurisdictions recognized by Health Canada for the purposes of the iLONO policy

National Food Service, Ministry of Health, Tel Aviv, Israel August 3, 2014 Guidelines: Use of Bacteriophages (bacteria killing viruses) in Food (Ref: 70275202)

Baltimore Business Journal May, 2014 Baltimore Business Journal recognized Intralytix as one of the top 25 biotechnology companies in 2014

Discover Magazine March, 2014 Infections Infected

Food Safety News March 20, 2013 New Spray Product Takes Aim at Salmonella on Poultry

Environmental Health Perspectives February 1, 2013 Phage Renaissance: New Hope against Antibiotic Resistance

Miller-McCune April 19, 2012 Defeating Bacteria From the Inside Out

Bacteriophage April 1, 2012 The strange history of phage therapy

The Mark Steiner Show September 28, 2011 Urbanite Radio Story: Healing Waters

Urbanite August 29, 2011 Healing Waters: In the Inner Harbor, the seeds of a medical breakthrough

Food Safety News May 9, 2011 Food Pathogen Interventions: Phasing in Phages

Journal of the American Veterinary Medical Association December 3, 2010 Searching for self-replicating antimicrobials

Los Angeles Times September 27, 2010 In The Works:? New Ways to Fight Bacteria

Gazette.Net Maryland Community Newspapers October 16, 2009 BioWatch: Baltimore biotech turns to the past for cutting-edge treatment

New York News - April 23, 2007 Spray to quell E. coli Baltimore company seeking FDA approval for viral substance to kill the bacteria on produce, raw meat

CBS News Video Spray For Bacteria-Free Meat Scientists in Baltimore, Maryland are harnessing billions of microscopic organisms in a war against bacteria such as E. coli, listeria and salmonella

CNN Video - September 19, 2006 Dr. Sanjay Gupta on the recent FDA approval of ListShield

PRESS RELEASE - August 19, 2006 FDA approves Intralytix's Food Safety Product (LMP 102)

Seed Magazine - Feb/Mar, 2006 Trail Phage Why antibiotics are so 1990's and how their complement may be squelched by the FDA

"Our World" Broadcast featuring Intralytix In the never-ending battle against bacterial infection

Voice of America - VOA News.com, October 27, 2003 "Our World" Broadcast featuring Intralytix In the never-ending battle against bacterial infection, antibiotics have been the main line of de

LA Times, March 31, 2003 Enlisting viruses to battle bacteria As even the most potent antibiotics lose the upper hand against bacteria, researchers are again exploring the potential of bacteriophage .

Bacteriophage therapy, pioneered in Stalin-era Russia, is attracting renewed attention in the West as a potential weapon against drug-resistant bugs and hard-to-treat infections

CBS News - 48 Hours, September 20, 2002 Silent Killers: Fantastic Phages? (CBS) After breaking his foot five years ago, Toronto bass player Alfred Gertler got an infection that antibiotics couldn't cure

Washington Techway, January 7, 2002 "Beating Superbugs" After years of research, phage therapy inches closer to market

US News & World Report, December, 2001 "Infectious Arms Race" Forging new weapons against resurgent bacterial killers

Newsweek International, December, 2001 "Superbug Killers" Western scientists discovered a potent weapon against antibiotic-resistant bacteria in an unlikely place . . .

FoodTech Source, September, 2001 "Phage-Enhanced Food Safety"

Agricultural Research Magazine, July, 2001 "Turning the Phage on Produce Pathogens" Tiny viruses, called phages, infect and kill bacteria naturally . . .

Smithsonian Magazine, October, 2000 "The Return of the Phage" As deadly bacteria increasingly resist antibiotics, researchers try to improve a World War I era weapon . . .

Science Service, Inc., June 3, 2000 "Viruses That Slay Bacteria Draw New Interest"

McMahonMed, June 20, 2000 "Viruses Called Bacteriophages Resurface As Viable Option To Fight Infections" See entire story

Washington Techway, March 13, 2000 "Planning for the day antibiotics fail" (Intralytix Inc's bacteriophage research plans)

New York Times, February 6, 2000 "A Stalinist Antibiotic Alternative"

DoubleTwist, January 21, 2000 "The return of bacteriophage therapies"